Villere ST Denis J & Co. LLC Acquires 1,556 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Villere ST Denis J & Co. LLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,442 shares of the company's stock after purchasing an additional 1,556 shares during the period. IDEXX Laboratories comprises about 2.3% of Villere ST Denis J & Co. LLC's investment portfolio, making the stock its 23rd biggest position. Villere ST Denis J & Co. LLC owned approximately 0.08% of IDEXX Laboratories worth $25,816,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its position in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares in the last quarter. National Pension Service lifted its position in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after acquiring an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC lifted its position in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after acquiring an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC lifted its position in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock valued at $1,450,000 after acquiring an additional 2,801 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, February 5th. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $533.75.

Insiders Place Their Bets

In other news, Director Sophie V. Vandebroek sold 344 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company's stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 over the last ninety days. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Trading Up 0.4 %

NASDAQ IDXX traded up $1.93 during trading hours on Wednesday, hitting $450.99. 578,701 shares of the company were exchanged, compared to its average volume of 707,372. The stock has a 50-day moving average price of $430.91 and a 200 day moving average price of $452.43. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The stock has a market cap of $36.93 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 3.35 and a beta of 1.37.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.